Vir Biotechnology’s VIR-5500 gets FDA Fast Track for prostate cancer
FDA granted Fast Track designation to VIR-5500, Vir Biotechnology’s PSMA-targeted PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer.